---
schema_version: "secwatch.filing_event.v1"
accession: "0001420720-24-000053"
form_type: "8-K"
ticker: "IBIO"
cik: "0001420720"
company_name: "iBio, Inc."
filed_at: "2024-11-12T23:59:59+00:00"
generated_at: "2026-05-30T01:42:48.398140+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# iBio Q1 fiscal 2025: net loss $4.0M ($0.46/sh), no revenue; advancing myostatin NHP study

## Summary
- No revenue for quarter ended Sep 30, 2024; net loss from continuing ops $4.0M ($0.46/sh) vs $5.1M ($4.24/sh) YoY.
- R&D and G&A expenses decreased ~20% YoY to $4.1M as part of cash preservation strategy.
- Cash, equivalents, and restricted cash $11.3M at Sep 30, 2024 (incl $0.2M restricted).
- Collaboration with AstralBio: lead molecule for muscle wasting/obesity dosed in NHP study; early readouts expected early 2025.
- Appointed Kristi Sarno as SVP of Business Development effective Aug 1, 2024.

## SEC filing metadata
- accession: 0001420720-24-000053
- form_type: 8-K
- ticker: IBIO
- cik: 0001420720
- company_name: iBio, Inc.
- filed_at: 2024-11-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1420720/000142072024000053/0001420720-24-000053-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1420720/000142072024000053/ibio-20240930x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001420720-24-000053
- JSON: https://secwatch.observer/filing/0001420720-24-000053.json
- Plain text: https://secwatch.observer/filing/0001420720-24-000053.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.